Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
View / Open Files
Authors
Cohen, Jeffrey A
Fox, Edward J
Giovannoni, Gavin
Hartung, Hans-Peter
Havrdova, Eva
Schippling, Sven
Traboulsee, Anthony
Compston, Alastair
Margolin, David H
Thangavelu, Karthinathan
Chirieac, Madalina C
Jody, Darlene
Xenopoulos, Panos
Hogan, Richard J
Panzara, Michael A
CARE-MS II and CAMMS03409 Investigators,
Publication Date
2017-09Journal Title
Neurology
ISSN
0028-3878
Volume
89
Issue
11
Pages
1117-1126
Language
eng
Type
Article
This Version
VoR
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Coles, A., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H., Havrdova, E., Schippling, S., et al. (2017). Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.. Neurology, 89 (11), 1117-1126. https://doi.org/10.1212/wnl.0000000000004354
Keywords
CARE-MS II and CAMMS03409 Investigators, Brain, Humans, Multiple Sclerosis, Relapsing-Remitting, Atrophy, Immunologic Factors, Disability Evaluation, Organ Size, Treatment Outcome, Follow-Up Studies, Time Factors, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, Alemtuzumab
Identifiers
External DOI: https://doi.org/10.1212/wnl.0000000000004354
This record's URL: https://www.repository.cam.ac.uk/handle/1810/270149
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
Licence URL: http://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended or similar items
The following licence files are associated with this item: